437717-43-6

Basic information

• Product Name: 3-(1,4-Dihydro-5-Methyl-4-oxo-7-propyliMidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzenesulfonic Acid
• Synonyms: 3-(1,4-Dihydro-5-Methyl-4-oxo-7-propyliMidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzenesulfonic Acid
• CAS NO: 437717-43-6
• Molecular Formula: C₁₇H₂₀N₄O₅S
• Molecular Weight: 392.43
• Product Categories: Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 437717-43-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.48g/cm³
• Vapor Pressure: 0.001-0.015Pa at 20-134.6℃
• Refractive Index: 1.669
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly, Heated), Methanol (Slightly, Heated)
• PKA: -0.81±0.50(Predicted)
• CAS DataBase Reference: 3-(1,4-Dihydro-5-Methyl-4-oxo-7-propyliMidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzenesulfonic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1,4-Dihydro-5-Methyl-4-oxo-7-propyliMidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzenesulfonic Acid(437717-43-6)
• EPA Substance Registry System: 3-(1,4-Dihydro-5-Methyl-4-oxo-7-propyliMidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzenesulfonic Acid(437717-43-6)

Safety Data

• Hazardous Substances Data: 437717-43-6(Hazardous Substances Data)

Usage

Description

3-(1,4-Dihydro-5-Methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzenesulfonic Acid is a complex organic compound with a unique chemical structure. It is characterized by its imidazo[5,1-f][1,2,4]triazin core, which is fused with a benzene ring and contains a sulfonic acid group. This molecule also features a 5-methyl and 4-oxo substituent, as well as a 7-propyl group attached to the triazine ring. Due to its structural features, it may exhibit specific chemical and physical properties that can be exploited in various applications.

Uses

Used in Pharmaceutical Industry:
3-(1,4-Dihydro-5-Methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzenesulfonic Acid is used as a side product in the synthesis of vardenafil (V098000) derivatives. Vardenafil is a phosphodiesterase type 5 (PDE5) inhibitor, commonly used for the treatment of erectile dysfunction. The presence of this compound in the synthesis process suggests that it may have potential applications in the development of new pharmaceutical agents or as an intermediate in the production of other active pharmaceutical ingredients.

InChI:InChI=1/C17H20N4O5S/c1-4-6-14-18-10(3)15-17(22)19-16(20-21(14)15)12-9-11(27(23,24)25)7-8-13(12)26-5-2/h7-9H,4-6H2,1-3H3,(H,19,20,22)(H,23,24,25)

Upstream product

• 224785-90-4 vardenafil 
• 224789-21-3 2-(2-ethoxy-phenyl)-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one 

Downstream Products

• 224785-90-4 vardenafil 
• 224786-13-4 2-{2-ethoxy-5-[4-acetyl-piperazine-1-sulphonyl]-phenyl}-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 224789-26-8 4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenelsulfonic acid chloride 

Relevant articles and documents

NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF

The present invention relates to compounds of formula (I) or formula (II) or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein said compound of formula (I) and said compound of formula II each comprises at least one ONO2 or ONO moiety; R1 is C1-C3alkyl; R2 is H, C1-C6alkyl, C3-C6cycloalkyl, C1-C2alkoxy, C2-C4alkenyl; R3 is C1-C4alkyl optionally substituted with C1-C2alkoxy, C3-C4cycloalkyl, C2-C4alkenyl; R4 and R5 are each independently H or C1-C6alkyl optionally substituted with F, OH, ONO, ONO2, COOH, C1-C3alkoxy, C3-C6cycloalkyl; or together with the nitrogen atom to which they are attached form a heterocyclic ring, wherein preferably said heterocyclic ring is selected from aziridine, azetidine, pyrollidine, piperidine, morpholine, piperazine, homo-piperazine, 2,5-diazabicyclo[2,2,1]heptane and 3,7-diazabicyclo[3,3,0]octane, wherein said heterocyclic ring is optionally substituted with independently one or more R6; R6 is C1-C6alkyl optionally substituted with independently one or more halogen, OH, ONO, ONO2, C1-C3alkoxy, C1-C3haloalkoxy, COOR7, NR8R9, C=NR10; R7 is H, or C1-C4alkyl optionally substituted with F, OH, ONO, ONO2, NR8R9; R8 and R9 are independently H, or C1-C4alkyl optionally substituted with ONO, ONO2; R10 is C1-C4alkyl optionally substituted with F, ONO, ONO2; C3-C6cycloalkyl; pharmaceutical compositions thereof, and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal.